Alternative Medications for Type 2 Diabetes When Metformin Cannot Be Used

First-Line Alternatives to Metformin

The American Diabetes Association recommends SGLT2 inhibitors as the preferred alternative for most patients with type 2 diabetes, particularly those with chronic kidney disease (eGFR ≥20 mL/min/1.73 m²), as they provide cardiovascular and renal protection independent of glucose lowering 1, 2
SGLT2 inhibitors should be initiated in most patients with type 2 diabetes and CKD with eGFR ≥20 mL/min/1.73 m², independent of HbA1c or need for additional glucose lowering, according to the Kidney Disease: Improving Global Outcomes (KDIGO) guideline 1, 2
These agents reduce CKD progression, heart failure, and cardiovascular disease risk independent of their glucose-lowering effects, with a strength of evidence rated as high 1
The cardiovascular and kidney benefits are consistent regardless of baseline albuminuria, including patients with normal albumin excretion, as stated by the American Heart Association 1
Available agents include canagliflozin, dapagliflozin, and empagliflozin, with specific eGFR thresholds varying by agent, according to the European Association for the Study of Diabetes (EASD) guideline 2
Common pitfall: Glucose-lowering efficacy decreases as eGFR declines, but cardiovascular and kidney benefits persist, as noted by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 2

Long-acting GLP-1 receptor agonists (dulaglutide, liraglutide, semaglutide) are the preferred add-on therapy for patients not achieving glycemic targets or unable to use metformin/SGLT2 inhibitors, as recommended by the American Association of Clinical Endocrinologists (AACE) 2
These agents reduce major adverse cardiovascular events (MACE) in patients with type 2 diabetes, with benefits extending to those without established cardiovascular disease, with a strength of evidence rated as moderate 2
GLP-1 receptor agonists reduce albuminuria and slow eGFR decline, as stated by the International Society of Nephrology (ISN) 2
Liraglutide showed significantly greater MACE risk reduction in patients with eGFR <60 mL/min/1.73 m² compared to those with eGFR ≥60 mL/min/1.73 m², according to the European Society of Cardiology (ESC) 2
Most formulations require no dose adjustment for renal impairment, except exenatide (avoid once-weekly formulation with eGFR <30 mL/min/1.73 m²), as noted by the Food and Drug Administration (FDA) 2
Weight loss benefit without increased hypoglycemia risk when used alone, as reported by the Endocrine Society 3, 4

Sulfonylureas reduce HbA1c by 1.0-1.5% and are appropriate for patients who cannot tolerate metformin, but carry significant hypoglycemia risk, as warned by the American Diabetes Association 5
Available agents in most markets include glimepiride, gliclazide, glipizide, and gliquidone, as listed by the World Health Organization (WHO) 5
Major caveat: High risk of hypoglycemia (10-20% with monotherapy, >50% when combined with insulin), particularly in elderly patients and those with renal/hepatic dysfunction, as cautioned by the National Institute on Aging (NIA) 3
Cause moderate weight gain, as reported by the Obesity Society 3
Gliquidone is preferred for patients with mild renal insufficiency, as recommended by the European Renal Association (ERA) 5
Cost advantage: Low cost compared to newer agents, as noted by the Agency for Healthcare Research and Quality (AHRQ) 3, 4

Insulin should be initiated without delay in patients with markedly symptomatic diabetes, HbA1c ≥10%, or blood glucose ≥300 mg/dL (16.7 mmol/L), as recommended by the American Diabetes Association 4
Basal insulin added to oral therapy lowers HbA1c by 0.7-2.5% on average, as reported by the Journal of Clinical Endocrinology and Metabolism 4
Major drawbacks: highest risk of hypoglycemia and weight gain among all glucose-lowering agents, as warned by the Food and Drug Administration (FDA) 3
Variable cost depending on formulation, as noted by the Centers for Medicare and Medicaid Services (CMS) 4

Step 1: Assess for cardiovascular disease, heart failure, or chronic kidney disease; if present, prioritize SGLT2 inhibitor (if eGFR ≥20 mL/min/1.73 m²), as recommended by the American College of Cardiology (ACC) 1, 2
Step 2: If no cardiovascular/kidney disease and patient needs moderate glucose lowering, consider GLP-1 receptor agonist if weight loss desired, as suggested by the Obesity Society 3, 4
Step 3: If severe hyperglycemia (HbA1c ≥10% or glucose ≥300 mg/dL), initiate insulin therapy with or without additional agents, as recommended by the American Diabetes Association 4
Step 4: Avoid in specific populations, such as TZDs in heart failure or fracture risk, as cautioned by the American Heart Association (AHA) 3

SGLT2 inhibitors: Monitor for genital mycotic infections, volume depletion, and diabetic ketoacidosis (rare), as warned by the Food and Drug Administration (FDA) 1
GLP-1 receptor agonists: Gastrointestinal side effects common initially; monitor for pancreatitis symptoms, as reported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 2
Sulfonylureas: Frequent glucose monitoring essential due to hypoglycemia risk, as recommended by the American Diabetes Association (ADA) 5
All agents: Adjust dosing based on renal function per specific agent requirements, as noted by the Kidney Disease: Improving Global Outcomes (KDIGO) guideline 2